Health Care · Biological Products, (No Diagnostic Substances)

BEAM Beam Therapeutics Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 174599990 filings
Russell 2000

BEAM at a glance

Beam Therapeutics Inc. (BEAM, SEC CIK 1745999) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as October 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Beam Therapeutics Inc. (BEAM) reported revenue of $139.7 million (up 120.0% from FY2024) and a net loss of $80.0 million. Diluted EPS was -$0.81.
  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Beam Therapeutics Inc. (BEAM) shares worth $1.2 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Evans John M. on October 16, 2026 of 25,000 shares at $23.98 per share.
  • In the last 90 days, BEAM insiders reported 0 open-market purchases ($0) and 3 open-market sales ($1.2M) on Form 4, a net sale of $1.2M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$139.7M
+120.0% vs prior year
Insiders · 90 days
0 buys · 3 sells
Net −$1.2M
13F holders
28 funds
$1.2B · −4 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Fully integrated precision genetic medicines platform based on proprietary base editing gene editing technology without DNA double-strand breaks
  • New products/segments: Announced BEAM-304 for phenylketonuria (PKU) and advancing in vivo LNP liver-targeted base editors BEAM-302 (AATD) and BEAM-301 (GSDIa)
  • Strategic shift: Prioritizing in vivo base editing delivery modalities for hematopoietic stem cells to expand sickle cell disease treatment beyond ex vivo autologous stem cell therapies
  • Quantitative metric: Completed dosing manufacture for risto-cel (BEAM-101) in 31 patients with mean editing efficiency 67.4% at 6 months and 72.8% at 12 months
  • Noteworthy fact: FDA alignment on accelerated approval pathway for BEAM-302 based on 12-month biomarker data, with planned enrollment of ~50 additional patients in pivotal expansion

Risk Factors

  • Cybersecurity risk oversight by Audit Committee with quarterly management updates and immediate alerts on significant incidents
  • Dependence on VP, IS with 25 years experience and CISSP and CISA certifications for cybersecurity program leadership
  • Company-wide annual employee training on data protection and incident response covering phishing and social engineering
  • Use of technology-based tools combined with employee programs to mitigate cybersecurity risks

Management Discussion & Analysis

  • Revenue $139.7M in 2025 vs $63.5M in 2024 and $377.7M in 2023, primarily from license and collaboration agreements
  • Net loss $80.0M in 2025 vs $376.7M loss in 2024 and $132.5M loss in 2023, accumulated deficit $1.6B at 2025 year-end
  • Hematology segment (ristocel) showing clinical progress with high editing efficiency (67.4% at Month 6, 72.8% at Month 12) and upcoming BLA submission planned for year-end 2026
  • $100M initial draw on $500M senior secured Credit Facility entered Feb 2026, interest rate SOFR +6.50%, no product sales revenue yet, capital raises expected for ongoing R&D
  • Forward outlook: dose expansions and clinical updates in 2026 for hematology and genetic disease programs; key risks include capital needs, regulatory approvals, and execution of clinical development

AI summary of the BEAM 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $0.3M, down $9.4M from $9.7M YoY
  • Net loss $134.4M vs $112.6M YoY, operating loss $141.3M vs $126.8M
  • R&D expense $110.1M vs $109.8M, G&A $31.5M vs $26.7M
  • Cash, equivalents and marketable securities $1.0B; operating cash outflow $305.4M
  • BEAM-302 expansion ongoing, pivotal-cohort dosing expected complete in first half of 2027; additional capital likely needed

Risk Factors

  • No material risk-factor changes identified relative to the 2025 Form 10-K
  • Financing risk: $100.4 million debt outstanding at 10.6% effective interest, maturing February 24, 2033
  • Liquidity risk: $1.0 billion cash, equivalents, and marketable securities expected to fund operations for at least 12 months
  • Regulatory risk: risto-cel development and commercialization subject to FDA acceptance and approval milestones
  • Collaboration risk: Biogen termination of FcRN program rights effective December 2026 ઘટાડે future collaboration potential

AI summary of the BEAM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Exhibit 99.1 contains the substantive earnings release and financial details

Item EX-99.1: Item EX-99.1

  • Q3 net loss widened to $134.4M, or $1.28 per share, from $112.6M, or $1.10, despite R&D remaining near $110.1M
  • Cash, equivalents and marketable securities fell to $1.0B from $1.2B at December 31, 2025
Filed Aug 4, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • BEAM-302 entered global pivotal dosing, advancing AATD toward potential accelerated approval and creating a major 2026 clinical catalyst
  • Risto-cel dosing completed in adult and adolescent BEACON patients, with updated data and potential BLA submission by year-end 2026

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Exhibit 99.1 contains the earnings release, the key source for revenue, cash runway and clinical spending details
Filed Jun 8, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Shareholders re-elected John Evans, John Maraganore, and Christi Shaw as Class III directors through the 2029 annual meeting
  • Deloitte & Touche LLP ratified as independent auditor for fiscal year ending December 31, 2026

AI summaries of BEAM 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for BEAM

Don't miss the next BEAM filing

  • Alerts as it files. A push when BEAM files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut BEAM, by share count.
  • Ask anything. An AI agent that reads every BEAM filing and answers with sources.

BEAM alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Evans John M.MOct 16, 2026$1.03
Evans John M.SellOct 16, 2026$23.98
Evans John M.MOct 16, 2026-
Evans John M.MOct 15, 2026$1.03
Evans John M.SellOct 15, 2026$23.57
Evans John M.MOct 15, 2026-
Cavanagh Bethany JSellOct 1, 2026$24.41
Ciaramella GiuseppeGSep 24, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$377.7M$63.5M$139.7M
Operating Income--$415.6M-$383.7M
Net Income-$132.5M-$376.7M-$80.0M
Op. Margin--654.3%-274.6%
Net Margin-35.1%-593.1%-57.2%
Balance Sheet
Total Assets-$1.1B$1.5B
Equity-$733.5M$1.2B
ROE--51.4%-6.5%
Per Share
EPS$-1.72$-4.58$-0.81
Cash Flow
Operating CF--$347.2M-$345.1M
CapEx$33.7M$8.9M$14.9M

Source: XBRL data in Beam Therapeutics Inc. (BEAM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate BEAM share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
BEAM shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$1.19B
Q2 202632$2.11B
Q1 202629$1.42B
Q4 202526$1.62B
Q3 202528$1.33B
Q2 202528$964.7M
Q1 202523$745.5M
Q4 202419$660.8M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 213 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

BEAM filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 3, 2026Analysis-
10-QNov 3, 2026Analysis
4Oct 16, 2026--
4Oct 2, 2026--
4Sep 25, 2026--
8-KAug 4, 2026Analysis-
10-QAug 4, 2026Analysis
4Jul 29, 2026--
4Jul 2, 2026--
4Jul 1, 2026--
4Jun 29, 2026--
4Jun 22, 2026--
8-KJun 8, 2026Analysis
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
10-QMay 7, 2026Analysis
8-KMay 7, 2026Analysis
SC 13GApr 29, 2026-
4Apr 6, 2026--
4Apr 6, 2026--
4Apr 6, 2026--

Related Health Care companies

All Health Care →

BEAM SEC filings: frequently asked questions

Are BEAM insiders buying or selling?

In the last 90 days, Beam Therapeutics Inc. (BEAM) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $1.2 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold BEAM stock?

As of September 30, 2026, the largest Beam Therapeutics Inc. (BEAM) holders among the 13F filers tracked by SignalX were ARK Investment Management ($288.6 million), BlackRock ($223.0 million), State Street Corp ($144.8 million), Vanguard Portfolio Management LLC ($119.8 million), Vanguard Capital Management LLC ($112.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was BEAM's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Beam Therapeutics Inc. (BEAM) reported revenue of $139.7 million (up 120.0% from FY2024) and a net loss of $80.0 million. Diluted EPS was -$0.81. The figures come from the XBRL data in the 10-K.

What are the main risks in BEAM's latest 10-K?

In the 10-K filed February 24, 2026, Beam Therapeutics Inc. (BEAM) flagged: Cybersecurity risk oversight by Audit Committee with quarterly management updates and immediate alerts on significant incidents. Dependence on VP, IS with 25 years experience and CISSP and CISA certifications for cybersecurity program leadership. (AI summary of the Risk Factors section.)

What did BEAM report in its latest 8-K?

Beam Therapeutics Inc. (BEAM) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest BEAM SEC filings?

Beam Therapeutics Inc. (BEAM) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on October 16, 2026.

What is BEAM's SEC CIK number?

Beam Therapeutics Inc. (BEAM)'s SEC Central Index Key (CIK) is 1745999. EDGAR lists every BEAM filing under that number.

Ask anything about BEAM

The research agent reads BEAM's filings, financials, insider trades and 13F holders, then answers with sources.